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Abstract
Given the recent scale-up of antiretroviral therapy (ART) in sub-Saharan Africa, we sought to
determine how often and at what levels do drug-resistant mutant variants exist in ART-naïve HIV
subtype C infected individuals. Samples from 10 ART-naïve Zambian individuals were subjected
to ultra-deep pyrosequencing (UDPS) to characterize the frequency of low-abundance drug
resistance mutations in the pol gene. Low-abundance clinically relevant variants were detected for
nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors
(NNRTIs) and protease inhibitors (PIs) in eight of the ten subjects. Intermediate to high-level
resistance was predicted for the majority of NRTIs. Mutations conferring resistance to most first-
line and some second-line therapy drugs were also observed. UDPS detected a number of
additional major resistant mutations suggesting that these individuals may have an increased risk
of virological failure after initiating ART. Moreover, the effectiveness of first-line and even some
second-line ART may be compromised in this setting.
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INTRODUCTION
As access to antiretroviral drugs is expanding in sub-Saharan Africa and second-line
treatments are often not readily available in the setting, it is imperative that adequate
assessment on the prevalence and transmission of drug resistance mutations is performed to
ensure optimization of treatment efficacy [1]. Antiretroviral therapy (ART) has been
successful in suppressing the human immunodeficiency virus (HIV), however it fails to
completely eliminate HIV from infected individuals and often elicits drug-resistant variants.
These mutations can persist in chronically HIV-infected, ART-naïve individuals, and the
prevalence of these resistance variants is likely to increase overtime [2]. In addition the
presence of these mutations has been demonstrated to have a negative impact on the
antiretroviral therapeutic response and shortens the time to the first virological failure [3].
Recently it has been demonstrated by ultra-deep pyrosequencing (UDPS), that resistance
variants as low as 1% are clinically relevant and can have a profound impact on treatment
outcome even in ART-naïve individuals that have recently initiated therapy [4, 5]. These
mutations found in less than 20% are not detectable by standard genotyping sequencing
techniques [4]. Furthermore, the low-abundance resistant variants can out-compete wild-
type virus under the selection pressures of antiretrovirals, ultimately lead to virologic failure
[4, 6, 7].
Currently, little is known about the prevalence of low-abundance drug-resistant variants that
exist in treatment-naïve patients especially in resource-limited settings such as sub-Saharan
Africa. While subtype B predominates in the U.S., over 50% of worldwide infections are
subtype C, with approximately 98% of HIV positive individuals in southern Africa [8]. One
such country in sub-Saharan Africa where we have been investigating is Zambia, where
subtype C is the predominant circulating HIV strain [9–12]. HIV treatment in Zambia
became available to the public sector in 2002 and was expanded in 2004 [13].
Previously, we demonstrated an increasing trend in the number of minor, borderline and
partial resistance mutations, as well as major resistance mutations after the availability free
ART in Zambia [11]. Here, we studied a subset of those patients by UDPS to assess the
frequency of low-level drug-resistant variants. To our knowledge this is the first time that
HIV-1 subtype C infected patients from a sub-Saharan African setting have been directly
evaluated for low-abundance drug-resistant viral variants using UDPS in comparison to
conventional sequencing. The present findings demonstrate that there is a high prevalence of
primary low-abundance drug-resistant variants against the current available treatment
regimen in drug-naïve individuals, which were not detected by conventional technologies
and may in turn be of clinical importance.
MATERIALS AND METHODS
Selection of Study Participants and Sample Preparation
Frozen HIV-1 proviral DNA samples from Zambian adults recently infected with HIV
subtype C were randomly selected from two cohorts of archived specimens. All subjects
were ART-naïve at the time of sample collection. A written informed consent was obtained
from all individuals. The study was conducted in accordance with the principles of the
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Helsinki Declaration and approved by the Zambian Ministry of Health, the Research and
Ethics Committee of the University Teaching Hospital in Lusaka, Zambia and the
Institutional Review Board of the University of Nebraska, Lincoln. The first cohort
comprised of four randomly selected Zambian women whose peripheral blood mononuclear
cells (PBMCs) DNA was available for the study. These samples were obtained in Lusaka,
Zambia between 1998 and 2002, before ART was available in Zambia to the public sector.
The second set was from two males and four females, collected in 2005 from a surveillance
of HIV subtyping and genotyping, after ART was freely available in Zambia. DNA
extraction from these PBMC specimens was previously described by Gonzalez et al. 2010
[11]. In order to determine the HIV copy number per μg of DNA in each sample, a real time
PCR amplification of the HIV LTR region was performed following the conditions
previously reported by Yun et al. 2002 [14].
PCR Amplification for Amplicon Library Preparation and UDPS
In order to determine the frequency of low-abundance ART resistance mutations within the
viral population of each study participant, UDPS was performed on barcoded overlapping
amplicons querying positions of HIV drug - resistance mutations in the protease (PR) and
reverse transcriptase (RT)-coding regions. The first step in the amplicon library preparation
was to generate a fragment 1686 bp amplicon containing the PR and the RT genes from the
DNA samples using the primers reported by Zhang et al. 2004 [15] and the FastStart High
Fidelity PCR System (Roche, Indianapolis, IN). For each sample, an average of 815 HIV
DNA copies was amplified to generate these amplicons. The amplicon library was generated
using eleven pairs of 6n barcoded primers adapted from Hoffman et al. 2009 [16]. These
overlapping fragments were amplified using the FastStart High Fidelity PCR System. The
positive PCR products were purified using the E.Z.N.A. Gel Extraction Kit (Omega Bio-
Tech, Norcross, GA) and quantitated by PicoGreen fluorescence (Invitrogen, Carlsbad, CA).
After pooling the amplicons in equimolar concentrations, the samples were processed and
sequenced on a Genome Sequencer FLX (Roche/454 Life Sciences, Branford, CT) at the
University of Nebraska Lincoln's Applied Genomics and Ecology core facility.
UDPS Sequence Analysis
The initial sequence reaction yielded 42,099 sequence reads that passed quality filtering. To
ensure high quality reads and to reduce the typical sequencing errors from pyrosequencing
the following quality control strategy was used. All reads that had ambiguous bases (N) or
whose lengths lay outside the main distribution, as well as inexact matches to the primer or
6-bp barcoding sequence were discarded. In addition reads with low quality scores (<20)
were excluded. The quality control procedure was implemented using an in-house Perl script
with both forward and reverse primers removed. An additional analysis was performed to
exclude sequence reads that were suspected to have resulted from G-to-A hypermutations
[17].
For each patient a direct clonal sequence served as a reference template in this study. Each
sequence read was mapped onto the direct PCR sequence using the Smith-Waterman
algorithm with the following parameters for the alignment; gap opening (−4), gap division
(4), match (+1), transition divisor (2) and transversion (−2). Drug-resistant mutations were
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identified using the 2009 surveillance drug resistant mutation (SDRM) list obtained from
Stanford University. Drug resistance was predicted by using the Stanford Genotypic
Resistance Interpretation Algorithm (version 6.0.8) available at http://hivdb.stanford.edu/
pages/algs/HIVdb.html.
To measure the accuracy of UDPS, an analysis based on four pNL43 clonal sequences
performed on the same plates with the clinical samples was carried out. The mean error rate
was estimated by comparing each UDPS sequencing read to the control sequence. The
overall mean mismatch error rate was 0.195%. To distinguish sequence errors from
authentic minor variants we adopted an exclusionary cutoff of 0.2% because of the a priori
interest in mutations such as those at known drug resistance positions. However, in order to
eliminate the possibility of artifacts, only mutations with frequencies greater than 1% were
included in the analyses.
RESULTS
Patient Characteristics
Ultra-deep pyrosequencing (UDPS) was applied to characterize the frequency of low-
abundance drug resistant variants in clinical samples obtained from 10 HIV-1 subtype C
infected patients. All selected patients were adults, HIV-1 positive and ART-naïve. Patients
were strategically chosen from a number of different towns in order to represent the
Zambian population. An average of 4093.5 HIV copies/ μg of DNA were isolated from each
sample, and a mean of 815 copies of HIV DNA were used to obtain the 1686 bp amplicon
containing the PR and the RT genes.
After a correction step was applied, UDPS generated on average 3961 (3192 – 4858) reads
per sample with a mean length of 211 bases. For each patient sample an average of 98.88%
of the GS FLX nucleotides were mapped onto each reference template previously derived
yielding an average coverage of approximately 600 sequence reads per base.
Comparison of UDPS and Standard Direct Sequencing Methods
The number of participants with a specific HIV ART-resistance major mutation detected by
standard direct sequencing and UDPS was analyzed and compared (Table 1). Eight ART-
resistance mutations were detected by UDPS, three for PIs, three for NRTIs and two for
NNRTIs, and only one ART-resistance mutation, K65R (NRTI), was observed in more than
one study participant. Only two mutations, M184V (NRTI) and K103N (NNRTI) were
detected by both UDPS and standard direct sequencing. These two mutations were confined
to detection by direct sequencing in a single patient (KA02). These results indicate that
UDPS identified all DRMs at levels ≥ 20% that were detected by standard sequencing.
Overall Rates of Drug-Resistance Mutations
For all subjects low-abundance drug resistant mutations were detected using the 2009
SDRM list. ART mutations detected by UDPS were categorized as having only low
abundance variants (prevalence level of <20%) and those with >20% prevalence level. Low-
abundant drug resistance mutations constituted 85% off all resistance mutations found (Fig.
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1). Only 15% of resistance mutations found in all subjects were detected in a frequency
>20%.
Specific Drug Resistance Mutations Per Class
Of the 10 subjects analyzed only one had a NNRTI mutations. These mutations were K103N
and G190A, and were present in 71% and 5% of the sequence reads respectively from a
single patient (KA02) (Table 2).
Similarly, only three NRTI mutations were detected in these patients One of these NRTI
mutations, K65R, which was detected in 6 of the 10 patients (Table 2). Another primary
major mutation that can confer NRTI resistance detected in low frequencies was K219R.
Similar to the NNRTI mutations the majority of major PI mutations were observed at a
prevalence rate of 1 to 20% (Fig. 1). Only three mutations were observed at frequencies
greater than 1%, two of which, D30N and M46I, were found in the same patient LUK06
(Table 3).
Predicted Genotype Resistance Using the Stanford Interpretation Algorithm
The resistance mutations associated with NRTIs from all patients was analyzed using the
Stanford algorithm (Table 4). While patients MO09 and KA02 had potential low-level
resistance and low-level resistance to D4T respectively, subjects CH02, 1690,924, LV04 and
1931 had intermediate resistance. Intermediate resistance to 3TC, ABC, DDI, FTC and TDF
was observed in patients CH02, 1690,924, LV04 and 1931. On the other hand, high level
resistance to 3TC, ABC and FTC was observed in patient KA02. In addition, a potential
low-level resistance to AZT was observed in patient MO09. As for NNRTIs, high level
resistance to EFV and NVP and partial low-level resistance to ETR and RPV were observed
in subject KA02 (Table 5). Resistance to the new generation NNRTI ETR was attributed to
the presence of G190A, which is one of the 13 mutations earmarked in the DUET study
trials with a response to ETR (Katlama C, et al. (2007) 4th IAS Conference on HIV
Pathogenesis, Treatment and Prevention http://www.ias2007.org).
Among PIs, patient LUK06 had HIV high level resistance to NFV partial low-level
resistance to ATV, FPV, IDV and LPV (Table 6). Meanwhile, patient 924 harbored partial
level resistance to ATV, NFV and SQV.
DISCUSSION
In this study we have used UDPS technology to detect minor virus variants in HIV-1 pol
from 10 drug-naive individuals from Zambia infected with HIV-1 subtype C. In recent
years, accumulating evidence has suggested that drug-resistant viral variants present at low
frequency in the population are clinically important, as they may have a profound impact on
treatment outcomes such as virologic failure to NNRTI-based therapy [4, 6, 18, 19]. The
detected frequency of these clinically relevant minority variants could be as low as 1% by
UDPS [4, 5], or 0.07% by allele specific PCR [18]. Conversely, not every study can
associate minor resistant variants with therapy failure [20–22]. Since 2004, first-line ART in
Zambia has comprised of a NRTI backbone, AZT or d4T plus lamivudine, in combination
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with a non-NRTI such as EFV or NVP. In July 2007, the Zambian Ministry of Health
introduced TDF as part of first-line therapy, making it the first African country to use it as a
nucleotide/NRTI backbone on a wide scale Mwinga A. (2007) HIV/AIDS Implementer's
meeting http://hivimplem enters.com/2007/). Early indications describing the clinical
outcomes among patients prescribed TDF have demonstrated a favorable benefit with
similar clinical and programmatic outcomes as AZT and d4T [23]. Results from our analysis
suggest that the viral quasispecies within these therapy-naïve individuals harbor low-
abundance resistance mutations that may compromise the first line therapy, including TDF,
currently available to patients in Zambia. Intermediate to high-level resistance was predicted
for the majority of NRTIs. Intermediate resistance to TDF was observed in 6 of the 10
individuals and attributed to the presence of K65R. This polymorphism was detected at an
average of 1.36% of the viral population of each these participants (Table 2). However, one
individual harbored M184V in combination with K65R, which increases the level of
susceptibility to TDF [24–26]. This K65R mutation is one of the most important HIV-1
drug-resistance mutations that confer decreased susceptibility to all clinically used NRTIs
except zidovudine. Recent clinical studies had shown the preferential emergence of K65R in
patients infected with subtype C from a range of different treatment regimens in sub-Saharan
Africa and elsewhere [27–29]. Additionally, low abundance of K65R have been detected by
UDPS in ART-naïve non-B subtypes and correlated with virological failure [5]. The
predominance of K65R in subtype C can be explained by a template pausing molecular
mechanism that facilitates the selection of K65R in the KKK motif at codons 64, 65, 66 of
the RT [30–32], and has been suggested that this characteristic of the KKK motif can lead to
PCR induced K65R [33]. However, a recent UDPS study were controls of different
percentages of K65R mutation were included and the theoretical and observed values of
K65R plasmid dilutions were similar (100%:94%, 5%:2.30% and 1%:0.90%), indicates that
the frequencies of K65R obtained by UDPS are reasonably accurate [34]. The presence of
TDF resistance in the population should be a concern for the current ART regimen.
Generally, second-line treatment is limited to boosted protease inhibitor based regimes for
patients failing first-line therapy. ETR offers a higher genetic barrier to the development of
viral resistance than the first-generation NNRTIs [35]. Yet, to date little is known about the
drug's potential effectiveness in sub-Saharan Africa although on a positive note over 90% of
patients previously exposed in southern Africa treatment programs would remain susceptible
to ETR [36]. Recently, UDPS of treatment-naïve and NNRTI experienced patients found
that ETR may be effective in treatment-naive patients with the most commonly occurring
NNRTI-resistant mutation K103N [37]. Interestingly, when we assessed the potential of
ETR resistance in our subjects, we observed a potential low-level resistance attributed to
G190A in only one out of the ten subjects. Therefore, a majority of the ART naive patients
in Zambia may still have a good optimum response to ETR.
Overall, the knowledge about the prevalence of drug-resistance mutations among both ART-
naïve and treated individuals in Zambia is limited [9–12]. A recent study that assessed the
mutational patterns and factors associated with baseline drug-resistant HIV present at the
initiation of baseline ART shows that resistance mutations may compromise the response to
standard first-line ART in 6% of patients in Lusaka, Zambia [10]. In addition, three of the
NRTI and one of the NNRTI mutations detected in our cohort were also observed in a
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cohort of Zambian children during 24 months of first-line ART [9]. By using UDPS, in
addition to the reported mutations from these studies, we have also detected additional
potential resistance variants, probably due to the detection limit of direct sequencing
employed by these studies. It is possible that many of the resistance mutants detected after
initiation of treatment in the treated children were likely to exist prior to treatment initiation
but were undetectable by conventional sequencing. Therefore, if an analysis of low-
abundance drug-resistance mutations is available prior to the initiation of treatment, an
optimal ART combination can be used from the beginning. It is likely that the UDPS
technology will continue to be improved and will become economically feasible to monitor
drug-resistant variants even in the developing country settings.
There are several limitations to the present investigation. First, this was a preliminary study
examining the feasibility of using UDPS in limited resource settings such as sub-Saharan
Africa. Therefore, our sample size is limited. However this analysis gives us an insight into
the level of primary antiretroviral resistance at a population level in Zambia. Secondly, a
widely recognized problem associated with UDPS is the possibility of under or
oversampling of the viral quasispecies pool due to a variable number of genome copy
numbers amplified from each subject. Given this variability there is always likelihood for
resampling the same template due to a low copy number. In turn this may distort the true
frequencies of variants within a giving population. Nevertheless it is unlikely that our
frequencies are over inflated by target resampling as there is a higher likelihood of
resampling the wild type variant as it is the predominant form within the population. Thus,
we may be actually underestimating the significance of the low-level drug-resistant
mutations in the population. The 454/Roche method similar to any other sequencing
technique involving PCR steps may induce base pair substitutions leading to drug resistance
mutations that are from PCR error [33]. Despite this challenge the detection of a large
proportion of the mutations found in this study is in agreement with previous reports
demonstrating that most of these mutations are authentic and currently affecting the first-line
treatment of patients in Zambia.
Unfortunately, in this study it was not possible to analyze viral RNA due to the difficulties
associated with the transport and storage of plasma. Therefore, resistance mutations were
analyzed from PBMCs. While proviral DNA provides a good account of archived resistance
mutations it may not represent those variants involved in active replication. However,
previous studies using UDPS have revealed that proviral DNA may hide segregated variants
[38, 39] that represent a minor subpopulation of the viral quasispecies and may be a source
of replication competent virus. Although it is not possible to evaluate the level of proviral
variants being expressed we can assume that some of them will generate viral progeny or
even recombine with replicating virus as previously shown [38]. As a result archived
provirus variants may preferential replicate at a given time point and undergo selective
expansion in the presence of ART, possibly affecting the therapeutic response. In fact it has
been now shown that the rates of detection of ART mutations in plasma RNA are similar to
those observed in proviral DNA from PBMC samples [40].
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CONCLUSIONS
In conclusion, we have demonstrated that UDPS can provide new insights on the burden of
drug-resistance in treatment-naïve subjects in developing countries. With this technology we
were able to identify and quantify an array of preexisting HIV-1 resistance variants that
were not detected by conventional sequencing approaches. Given the increasing prevalence
of subtype C infections worldwide it is vital that minor drug-resistance variants are
identified to ensure optimization of treatment regimens.
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Fig. (1).
Proportion of resistance mutations within the viral population of subtype C infected ART-naïve Zambian individuals. Proportion
of mutations detected by UDPS with an abundance of 1 to 20% and > 20% of the virus population. Each bar indicates
percentages of NNRTIs (dark gray), NRTIs (black), PIs (gray) and overall mutations (light gray) that comprise each prevalence
range category.
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Table 1
HIV ART Resistance Mutations Detected by Direct and Ultra-Deep Sequencing
Resistance Mutations
Sequencing Method*
Direct Only Ultra-Deep Only Direct and Ultra-Deep
PI
D30N 0 1 0
M46I 0 1 0
G73S 0 1 0
NRTI
K65R 0 6 0
M184V 1 1 1
K219R 0 1 0
NNRTI
K103N 1 1 1
G190A 0 1 0
*Number of participants with a specific HIV ART resistance major mutation detected by a specific sequencing method.
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Table 4
Genotypic Resistance to NRTIs in ART-Naïve Individuals as Determined by the Stanford Interpretation
Algorithm
Subject ID Resistance Mutations
Predicted Susceptibility
3TC ABC AZT D4T DDI FTC TDF
MO09 K219R S S PLLR PLLR S S S
1994 n S S S S S S S
CH02 K65R I I S I I I I
1690 K65R I I S I I I I
LUK06 n S S S S S S S
MO03 n S S S S S S S
KA02 K65R, M184V R R S LLR I R I
924 K65R I I S I I I I
LV04 K65R I I S I I I I
1931 K65R I I S I I I I
List of abreviations: 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; DDI, didanosine; FTC, emtricitabine; TDF, tenofovir; I,
intermediate resistance; LLR, low-level resistance; PLLR, potential low-level resistance; R, high-level resistance; S, susceptible; n, no resistance
mutations.
Curr HIV Res. Author manuscript; available in PMC 2014 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gonzalez et al. Page 16
Table 5
Genotypic Resistance to NNRTIs in ART-Naïve Individuals as Determined by the Stanford Interpretation
Algorithm
Subject ID Resistance Mutations
Predicted Susceptibility
EFV ETR NVP RPV
MO09 n S S S S
1994 n S S S S
CH02 n S S S S
1690 n S S S S
LUK06 n S S S S
MO03 n S S S S
KA02 K103N, G190A R PLLR R PLLR
924 n S S S S
LV04 n S S S S
1931 n S S S S
List of abreviations: EFV, efavirenz; ETR, etravirine; NVP, nevirapine; I, intermediate resistance; RPV, rilpivirine; LLR, low-level resistance;
PLLR, potential low-level resistance; R, high-level resistance; S, susceptible; n, no resistance mutations.
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Table 6
Genotypic Resistance to Pis in ART-Naïve Individuals as Determined by the Stanford Interpretation
Algorithm
Subject ID Resistance Mutations
Predicted Susceptibility
ATV/r DRV/r FPV/r IDV/r LPV/r NFV SQV/r TPV/r
MO09 n S S S S S S S S
1994 n S S S S S S S S
CH02 n S S S S S S S S
1690 n S S S S S S S S
LUK06 D30N, M46I PLLR S PLLR PLLR PLLR R S S
MO03 n S S S S S S S S
KA02 n S S S S S S S S
924 G73S PLLR S S S S PLLR PLLR S
LV04 n S S S S S S S S
1931 n S S S S S S S S
List of abreviations: ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; FPV/r, fosamprenavir/ritonavir; IDV/r, indinavir/ritonavir; LPV/r,
lopinavir/ritonavir; NFV, nelfinavir; SQV/r, saquinavir/ritonavir; TPV/r, tipranavir/ritonavir; I, intermediate resistance; LLR, low-level resistance;
PLLR, potential low-level resistance; R, high-level resistance; S, susceptible; n, no resistance mutations.
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